Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study analyses the effect of intravenous branched chain amino acids (BCAA) on overt HE
in patients with ACLF. The investigators plan to study the efficacy of combining intravenous
BCAA with lactulose versus lactulose alone in the medical management of overt HE in patients
with ACLF and its impact on overall survival and improvement in grade of HE.
Phase:
Phase 1
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research